✦ LIBER ✦

Commentary: HBsAg levels as predictor of sustained response to peginterferon in HBeAg-negative chronic hepatitis B – author's reply

✍ Scribed by C.-Y. Peng

Book ID: 108606631
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 35
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2012.05020.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Commentary: HBsAg levels as predictor of

Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B

✍ S. J. Hadziyannis 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Early serum HBsAg level as a strong pred

Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ C.-Y. Peng; H.-C. Lai; Y.-F. Li; W.-P. Su; P.-H. Chuang; J.-T. Kao 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

Hepatitis B virus surface antigen levels

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K. K. La 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB

Bristol-Myers Squibb, Gilead, and Novartis. He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on th

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.